Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tiragolumab plus atezolizumab active in PD-L1+ NSCLC

Key clinical point: Targeting TIGIT, an inhibitory receptor expressed on immune cells, appears to complement activity of anti–programmed death–ligand 1/PD-1 antibodies in patients with lung cancer.

Major finding: Tiragolumab plus atezolizumab produced responses in 6 of 13 patients (46%) with PD-L1-positive non–small cell lung cancer, and 2 patients achieved a complete response.

Study details: A phase 1 study of 71 patients with advanced solid tumors.

Disclosures: The study was sponsored by Genentech. The presenter disclosed relationships with Genentech/Roche, Five Prime, Gilead, Lilly, and other companies.


Bendell JC et al. AACR 2020, Abstract CT302.